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Population Impact and Effectiveness of Monovalent
Rotavirus Vaccination in Urban Malawian Children
3 Years After Vaccine Introduction: Ecological and
Case-Control Analyses
5 NQ1 aor Bar-Zeev,1,2,a Khuzwayo C. Jere,1,2,a Aisleen Bennett,1,2 Louisa Pollock,1,2 Jacqueline E. Tate,3 Osamu Nakagomi,4 Miren Iturriza-Gomara,2
Anthony Costello,5 Charles Mwansambo,6 Umesh D. Parashar,3 Robert S. Heyderman,1,7,8 Neil French,1,2 and Nigel A. Cunliffe2; for the VACSURV ConsortiumQ2
1Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre; 2Institute of Infection and Global Health, University of Liverpool, United Kingdom;
3Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 4Graduate School of
Biomedical Sciences, Nagasaki University, Japan; 5Institute of Global Health, University College London, United Kingdom; 6Ministry of Health, Lilongwe, Malawi; and 7Liverpool School of Tropical
10
Medicine, and 8Division of Infection and Immunity, University College London, United Kingdom
BackgroundQ4 . Rotavirus vaccines have been introduced in many low-income African countries including Malawi in 2012. Despite
early evidence of vaccine impact determining persistence of protection beyond infancy, the utility of the vaccine against speciﬁc
rotavirus genotypes and effectiveness in vulnerable subgroups is important.
Methods. We compared rotavirus prevalence in diarrheal stool and hospitalization incidence before and following rotavirus vac-
15 cine introduction in Malawi. Using case-control analysis, we derived vaccine effectiveness (VE) in the second year of life and for
human immunodeﬁciency virus (HIV)–exposed and stunted children.
Results. Rotavirus prevalence declined concurrent with increasing vaccine coverage, and in 2015 was 24% compared with pre-
vaccine mean baseline in 1997–2011 of 32%. Since vaccine introduction, population rotavirus hospitalization incidence declined in
infants by 54.2% (95% conﬁdence interval [CI], 32.8–68.8), but did not fall in older children. Comparing 241 rotavirus cases with 692
20 test-negative controls, VE was 70.6% (95% CI, 33Q5 .6%–87.0%) and 31.7% (95% CI, −140.6% to 80.6%) in the ﬁrst and second year of
life, respectively, whereas mean age of rotavirus cases increased from 9.3 to 11.8 months. Despite higher VE against G1P[8] than
against other genotypes, no resurgence of nonvaccine genotypes has occurred. VE did not differ signiﬁcantly by nutritional status
(78.1% [95% CI, 5.6%–94.9%] in 257 well-nourished and 27.8% [95% CI, −99.5% to 73.9%] in 205 stunted children; P = .12), or by
HIV exposure (60.5% [95% CI, 13.3%–82.0%] in 745 HIV-unexposed and 42.2% [95% CI, −106.9% to 83.8%] in 174 exposed
25 children; P = .91).
Conclusions. Rotavirus vaccination in Malawi has resulted in reductions in disease burden in infants <12 months, but not in
older children. Despite differences in genotype-speciﬁc VE, no genotype has emerged to suggest vaccine escape. VE was not demon-
strably affected by HIV exposure or stunting.
Keywords. rotavirus vaccine; population impact; vaccine effectiveness; developing countries; case-control.
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Following randomized trial evidence of rotavirus vaccine efﬁca-
cy in low-income settings [1] that led the World Health Orga-
nization (WHO) to recommend global implementation [2], as
35 of August 2015, 35 low-income African countries have intro-
duced rotavirus vaccination into their Expanded Programme
on Immunization schedules with support from Gavi, the Vac-
cine Alliance [3].Monovalent rotavirus vaccine (RV1) effective-
ness (VE) and cost-effectiveness have been demonstrated
40following vaccine rollout in low-income, high-burden settings
[4–6]. In Malawi, one of the ﬁrst African countries to introduce
rotavirus vaccine into its national immunization program in
2012, RV1 reduced population rotavirus hospitalization burden
by 43% (95% conﬁdence interval [CI], 18%–61%) with an effec-
45tiveness compared to test-negative controls of 64% (95% CI,
24%–83%) against severe rotavirus gastroenteritis [5].
Despite early evidence of rotavirus vaccine impact in low-
income settings, it remains important to determine VE against
additional endpoints of public health signiﬁcance, particularly
50with an accelerated immunization schedule at 6 and 10 weeks
that was not examined in clinical trials. Demonstrating persis-
tence of protection beyond infancy is important as previous
case-control studies in South America and a randomized trial
in Malawi, respectively, found lower effectiveness and efﬁcacy
55in second year of life, suggesting the possibility of waning
immunity [7–9]. Likewise, the utility of the WHO-scheduled
aN. B. and K. C. J. contributed equally to this work.
Correspondence: N. Bar-Zeev, Malawi-Liverpool-Wellcome Trust Clinical Research Pro-
gramme Malawi, College of Medicine, University of Malawi, and Institute of Infection & Global
Health, University of Liverpool, PO Box 30096, Chichiri, Blantyre 3, UK (naor.bar-zeev@liverpool.
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vaccine in speciﬁc high-risk subgroups, such as malnourished
or human immunodeﬁciency virus (HIV)–exposed children,
has not been fully established. Poor nutrition is associated
60 with gastrointestinal morbidity [10], and HIV-exposed children
(those born to an HIV-infected mother) face persistent immu-
nological defects and a higher disease burden, even if they are
uninfected with HIV [11, 12]. In a randomized trial in South
Africa, RV1 produced satisfactory immune responses in HIV-
65 infected infants [13, 14], and subsequent case-control studies
with a second dose at 14 weeks showed comparable VE among
HIV-exposed but uninfected and HIV-unexposed children
[4]. The effectiveness among these risk groups of the WHO
globally recommended 6- and 10-week schedule has not been
70 investigated.
A wide diversity of rotavirus strains has been reported in the
past 2 decades inMalawi, with emergence of G8 genotypes in the
1990s [15], G12 in the mid-2000s [16] and G2 just prior to vac-
cine introduction in 2012 [5]. Additionally, despite trial evidence
75 of heterotypic (cross-serotype) protection provided by the mono-
valent G1P[8] vaccine [17], conﬁrming genotype-speciﬁc VE and
the absence of vaccine escapes is important [18].
Utilizing an existing surveillance platform in Blantyre, Mala-
wi [19], to extend our early observations [5], we sought to ad-
80 dress questions of waning effectiveness with age, of effectiveness
in select high-risk populations, and of effectiveness against a va-
riety of circulating strains. We have analyzed prevaccine, senti-
nel hospital-based surveillance dating back to 1997 [16] and
undertaken postvaccine case-control studies [5].
85 METHODS
Baseline Surveillance
From 1 January 1997 to 31 July 2009, we conducted surveillance
for diarrheal disease at the Queen Elizabeth Central Hospital
(QECH) in Blantyre, Malawi [16, 20]. QECH is a government-
90 funded teaching hospital for the southern region of Malawi,
and provides free healthcare to a population of about 1.3 million
persons. It is the referral facility for a network of 23 government
primary health centers. We recruited children aged <5 years pre-
senting with acute diarrhea to QECH. Study nurses actively re-
95 cruited children in the Accident and Emergency Department
Monday through Friday, and selectively sought to capture all ad-
mitted children and those with short-stay (approximately 4
hours) for observed oral rehydration.
Enhanced Surveillance
100 From January 2012, our surveillance activities at this site were
enhanced in light of impending introduction of rotavirus vac-
cine and included additional inpatient pediatric wards (nursery,
malnutrition, main ward, and special care ward) with Monday
through Saturday surveillance (Sunday admissions were usually
105 recruited on Monday morning). Since January 2012 we ob-
tained demographic, clinical, and anthropometric data through
parental interview and review of medical notes and physical ex-
amination. Severity was measured using the Ruuska-Vesikari
scale [21], and stunting was deﬁned as length-for-age z score
110< −2. We obtained rotavirus vaccination status from govern-
ment-issued patient-held vaccine record (the “health passport”)
and excluded from analysis those with a missing record. These
surveillance platforms and case ascertainment methods have
been described in detail previously [5, 19].
115Laboratory Methods
During both surveillance periods, we collected stool for rotavirus
testing by enzyme immunoassay (EIA) (Rotaclone, Meridian
Bioscience, Cincinnati, Ohio). EIA-positive stools underwent
VP7 (G) and VP4 (P) genotyping using qualitative, heminested
120multiplex reverse transcription–polymerase chain reaction (PCR)
as previously described [22].We screened all EIA-positive stools
collected from vaccinated children for vaccine strain shedding
using a RV1 NSP2-speciﬁc quantitative PCR assay [23]. HIV
status of the mother was obtained from her health passport, or
125was determined from the child ﬁnger-prick blood samples using
2 sequential antibody rapid tests (Determine, Abbott Laborato-
ries, Germany; Uni-Gold, Trinity Biotech, Ireland) or by DNA
PCR in infants aged <12 months according to national guide-
lines [24]. A child was considered HIV exposed but uninfected
130if the mother was documented as HIV infected or tested posi-
tive on sequential rapid test but her child had negative rapid test
alone or a negative DNA result regardless of rapid test result.
Children whose mother’s status was unknown and who them-
selves had a negative rapid test were considered unexposed.
135Analysis
Because our surveillance in the year before and since vaccine in-
troduction was enhanced, we cannot directly compare popula-
tion-based incidence rates for the 2 surveillance periods (from 1
January 1997 to 31 July 2009 and from January 2012 onward,
140respectively). Thus, we relied on the comparison of rotavirus
prevalence in diarrheal stools across these periods, using the
Royston χ2 test for trend to test the null hypothesis of no change
in prevalence over time [25]. We report Wilson conﬁdence
bounds around binomial proportions [26]. We also present
145genotyping data from our historical archive, and compare his-
torical baseline genotype-speciﬁc prevalence in diarrheal stool
with current prevalence in the post–rotavirus vaccine era.
For the second surveillance period, we calculated population
incidence of hospitalized rotavirus and of genotype-speciﬁc ro-
150tavirus in infants <12 months old and in children aged 1–4
completed years, as the number of cases observed divided by
100 000 age-speciﬁc Blantyre population derived from midyear
population projections from the 2008 population census [27].
Projections were derived through linear extension of annual in-
155crease in age-speciﬁc population in the intercensal period going
back to 1998. We then calculated the ratio of the incidence rate
for the period 1 January to 30 June 2012 before vaccine was
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introduced to the rate in equivalent calendar periods for 2013,
2014, and 2015. We report vaccine impact as 1 minus this inci-
160 dence rate ratio [28]. Because there was no catch-up campaign
when rotavirus vaccine was introduced to Malawi, for children
aged >1 year we compare the rates in 2014 and 2015 against the
mean rate for 2012 and 2013. This is because 2013 was effective-
ly a prevaccine year for this group. For each year we report the
165 impact compared to baseline together with the calculated VE
derived for these same years. Vaccine effectiveness is derived
from logistic regression as 1 minus the adjusted odds ratio (OR)
of receiving 2 doses of rotavirus vaccine in EIA-conﬁrmed ro-
tavirus cases compared with diarrheal EIA-negative controls.
170 We adjusted the OR for year and month of presentation and
for age. In addition, our study protocol deﬁned as secondary
endpoints the evaluation of VE by year of age, by genotype,
in HIV-exposed children and in malnourished children. For
year of age and genotype, we derived VE using the deﬁned sub-
175 group as cases and comparing rotavirus-negative controls. In
the case of HIV and malnutrition, we also conducted stratiﬁed
analysis comparing VE among children with the condition of
interest against the VE in children without the condition, and
tested the null hypothesis of homogeneity of the VE across stra-
180 ta using the Cochran-Mantel-Haenszel test [29]. We ﬁrst en-
sured no signiﬁcant interaction between the strata of interest
and vaccine status (results not shown). All VE estimates include
data from the date of introduction 29 October 2012 to 30 June
2015. Analysis was conducted using Stata 12.1 (StataCorp, Col-
185 lege Station, Texas). The endpoints reported in this paper were
protocol predeﬁned but represent unpowered secondary analyses.
Ethics
Ethical approval was provided by the National Health Sciences
Research Committee, Lilongwe, Malawi (867), and by the Re-
190 search Ethics Committee of the University of Liverpool, United
Kingdom (000490). Written consent was obtained from the
parents or guardians of participating children.
RESULTS
Vaccine Coverage Since Introduction
195 Among vaccine age-eligible infants <12 months presenting with
rotavirus EIA-negative diarrhea, vaccine coverage with 2 doses
of RV1 was 74.6% in 2013, 92.4% in 2014, and 95.1% in 2015.
Among rotavirus-negative children >1 year of age, the coverage
rates were, respectively 18.4%, 70.1%, and 87.3%.
200 Long-term Prevalence of Rotavirus and Speciﬁc Genotypes Over Time
Between 1 July 1997 and 30 June 2015, we recruited 5875 chil-
dren with diarrhea. A comparison of postvaccine rotavirus
prevalence among children with diarrhea aged <5 years against
our historical archive shows lower prevalence than in the prior
205 decade of surveillance (Figure 1Q6 ). Annual prevalence in the pre-
vaccine years 1997–2009 was 32.4% (Wilson 95% CI, 31.1%–
33.8%), whereas in the postvaccine years 2013–2015 it was
29.3% (Wilson 95% CI, 27.0%–31.7%) (t test P = .029). In the
period January–June of 2012–2015, rotavirus prevalence in
210stool was 44.1%, 41.7%, 29.1%, and 24.3%, respectively. Geno-
type-speciﬁc prevalence in diarrheal rotavirus-EIA positive
stool varied from year to year and no long-term trend is appar-
ent (Figure 2). However for G1P[8], prevalence is lower since
vaccine introduction than at any time during historical surveil-
215lance at our site (Figure 3). In the calendar periods 1 January–30
June of 2014 and 2015 combined, G1P[8] has had a nonsignif-
icant decline of 54.0% (95% CI, −13.4% to 81.3%; P = .109)
compared with prevaccine baseline of 1 January to 30 June
2012. On speciﬁc testing, none of the G1 rotaviruses was vaccine
220virus (data not shown). A transient increase was observed for
G2P[4] from January 2012 to April 2014, but overall for the
same period of 1 January–30 June of 2014 and 2015 compared
with preintroduction levels, there was a nonsigniﬁcant increased
incidence of G2P[4] of 10.5% (95% CI, −61.1% to 213.5%;
225P = .88).
Figure 1. Rotavirus (RV) prevalence in diarrheal stools at Queen Elizabeth Central
Hospital, Blantyre, Malawi, 1997–2015.
Q13
Figure 2. Three-year moving average of genotype-specific prevalence in rotavirus
enzyme immunoassay–positive stools, 1999–2009 and 2011–2015.
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Rotavirus Hospitalization Incidence in Infants <12 Months, 2012 to 2015
Population incidence of rotavirus hospitalization and rotavirus
prevalence in diarrheal stool during the enhanced surveillance
period 2012–2015 are presented in Table 1. There was a signiﬁ-
230 cant reduction in population incidence of rotavirus hospitaliza-
tion in infants over time. A before–after comparison of
January–June 2012 (prevaccine) with the mean incidence for
January–June of the years 2013–2015 shows a reduction in in-
fants of 48.2% (95% CI, 36.5%–57.7%; P < .0001). A year-by-
235 year comparison for each January–June periods compared to
2012 in infants showed no reduction in 2013, a reduction of
43.2% (95% CI, 18.0%–60.7%; P = .0026) in 2014, and of 54.2%
(95%CI, 32.8%–68.8%; P < .0001) in 2015 (Table 1 and Figure 4).
Rotavirus Hospitalization Incidence in Children Aged 1–4 Years,
240 2012–2015
RV1 was introduced in Malawi without any catch-up campaign,
so children aged 1 year and older were ineligible to receive
vaccine until October 2013. In comparison to January–June
2013, the same calendar months in 2014 saw a decline of
24538.7% (95% CI, 6.3%–59.9%; P = .024) and in 2015 of 47.4%
(95% CI, 18.4%–66.1%; P = .004). But when comparing the
mean incidence for January–June of the years 2013–2015
against a baseline of January–June 2012 (prevaccine), an in-
crease in population incidence of 38.5% (95% CI, −1.9% to
25095.4%; P = .06) was found. Given year-on-year variability in in-
cidence in this group, discerning any trend is difﬁcult (Table 1
and Figure 4).
Rotavirus Age Distribution
Since vaccine introduction, rotavirus cases have occurred at an
255older age; the mean age in months was 9.3 (standard deviation
[SD], 5.2) preintroduction and is now 11.8 (SD, 5.8) months
(P < .001). In 2015, children >1 year of age constituted 42
(46.7%) of 90 rotavirus cases. No age shift occurred in nonrota-
virus diarrhea cases (mean age in months, 13.5 [SD, 9.5] prein-
260troduction and 13.1 [SD, 8.3] postintroduction; P = .53;
Figure 5).
Figure 3. G1P[8] prevalence among rotavirus enzyme immunoassay–positive di-
arrheic stools at Queen Elizabeth Central Hospital, Blantyre, Malawi, 1 January
1999–31 December 2009 and January 2012–June 2015. Abbreviation: CI, confi-
dence interval.
Table 1. Q15Rotavirus Hospitalization Incidence and Rotavirus Prevalence in Diarrheic Stool, 2012–2015
Year
Infants <1 y Children 1–4 y
Incidencea
Rotavirus EIA
Total Incidencea
Rotavirus EIA
TotalNo. Positive No. Negative No. Positive No. Negative
2012 268.7 79 (49%) 82 (51%) 161 (100%) 32.8 19 (28%) 48 (71%) 67 (100%)
2013 284.2 87 (40%) 132 (60%) 219 (100%) 114.6 57 (46%) 68 (54%) 125 (100%)
2014 152.5 52 (31%) 115 (69%) 167 (100%) 70.2 39 (27%) 107 (73%) 107 (100%)
2015 123.1 42 (23%) 144 (77%) 186 (100%) 60.3 37 (24%) 115 (76%) 152 (100%)
Total 260 473 733 Total 152 338 490
Pearson χ2 = 29.6, P < .001
Royston χ2 for trend = 29.6, P < .0001
Pearson χ2 = 17.1, P = .001
Royston χ2 for trend = 5.5, P = .019
Abbreviation: EIA, enzyme immunoassay.
a Incidence from January to June per 100 000 age-adjusted Blantyre population.
Figure 4. Monthly cases of rotavirus at Queen Elizabeth Central Hospital, Blan-
tyre, Malawi, 1 January 2012–30 June 2015. Abbreviation: RVV, rotavirus vaccine.
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Rotavirus Vaccine Effectiveness
Crude VE overall since vaccine introduction was 60.4% (95% CI,
25.4%–79.0%; P = .004), whereas adjusting for age, year, and
265 month of admission gave VE of 58.3% (95% CI, 20.2%–78.2%).
Vaccine effectiveness estimates by age group, byHIV status, by
nutrition status, by disease severity, and by genotype are shown
in Table 2. Notably, the point estimate of VE was markedly
lower in children in the second year of life than in infants,
270 though fewer rotavirus cases in this age group result in wide
conﬁdence bounds. Although the number of HIV-exposed but
uninfected children was not high, VE was of comparable mag-
nitude to that in unexposed children, and there was no evidence
that VE differs by HIV exposure status. In well-nourished chil-
275 dren, the point estimate of VE was substantially higher than in
stunted children, but the conﬁdence bounds were wide and this
difference was not statistically signiﬁcant. There was no obvious
relationship between VE and disease severity measured by
Ruuska-Vesikari score. Despite a comparable number of G2
280 and G12 genotypes to G1 genotypes, the point estimate of VE
was lower and not signiﬁcant against the former genotypes, and
was signiﬁcant and higher against the G1 genotype (Table 2).
Correspondingly, VE was comparable for P[6] and P[8], but
against P[4] VE was lower and nonsigniﬁcant (Table 2).
285 DISCUSSION
In the current post–rotavirus vaccine era in Malawi, rotavirus
prevalence rates are the lowest since surveillance began almost
18 years ago [16]. Each year since vaccine introduction and
concurrent with increasing vaccine coverage, we have observed
290 successive reductions in population incidence of rotavirus hos-
pitalization. We found sustained VE of 58.3% (95% CIQ7 , 20.2%–
78.2%), which is comparable to VE estimates reported in a prior
clinical trial in Malawi [1].However, consistent with prior studies
[7–9] we also observed lower VE in children aged 1–2 years and
295no evident declines in incidence in children >1 year old. Al-
though it is plausible that in the presence of herd protection,
unvaccinated children are less exposed to disease, thereby lower-
ing apparent VE, modeling has shown the impact of such epide-
miological phenomena to be marginal [30]. In our population
300with high vaccine coverage, we have observed an increase in
the mean age of rotavirus cases, but not of rotavirus-negative di-
arrhea cases. The absolute burden of disease in the older age
group has not increased, however. This is consistent with a reduc-
tion in the burden of hospital-attended disease disproportionate-
305ly affecting those who have most recently had the vaccine and a
time-dependent decay in VE. This ﬁnding suggests waning im-
munity and will require continued monitoring. If herd protection
is not achieved with this vaccine, waning immunity is likely to
Table 2. Adjusteda Vaccine Effectiveness in Children by Subgroup Q14
Subgroup
Cases/
Controls, No.
2-Dose VE, %
(95% CI)
P
Value
All 241/692 58.3 (20.2–78.2) .008
Age <12 mo 167/467 70.6 (33.6–87.0) .003
Age 12–23 mo 71/201 31.7 (−140.6 to 80.6) .552
Age 12–31 moc 73/225 28.8 (−147.5 to 79.5) .594
HIV unexposed 191/554 60.5 (13.3–82.0) .021
HIV exposed and
uninfectedd
48/126 42.2 (−106.9 to 83.8) .400
CMH test .912
Well nourishede 74/183 78.1 (5.6–94.9) .042
Stuntedf 53/152 27.8 (−99.5 to 73.9) .530
CMH test .115
Vesikari score ≤10g 42/187 66.3 (−5.0 to 89.2) .061
Vesikari score >10 149/368 59.7 (9.3–82.1) .028
Vesikari score >15 49/116 65.2 (−16.5 to 89.6) .087
G1P[8]h 36/692 82.1 (44.6–94.2) .003
G2P[4] 43/692 34.9 (−135.0 to 82.0) .512
G1 (any P type) 98/692 70.7 (20.1–89.3) .016
G2 (any P type) 61/692 45.9 (−47.0 to 80.1) .228
G12 (any P type) 38/692 51.0 (−88.5 to 87.3) .299
P[4] (any G type) 58/692 32.8 (−109.1 to 78.4) .493
P[6] (any G type) 72/692 68.1 (14.9–88.1) .022
P[8] (any G type) 50/692 71.0 (20.6–89.4) .016
Entirely heterotypic: any
non-G1, non-P[8]
112/692 46.6 (−21.7 to 76.6) .136
Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel test of homogeneity
across strata [29]; HIV, human immunodeficiency virus; VE, vaccine effectiveness.
a All analyses adjusted for age, year, and month of admission.
b First year since RV1 introduction: 29 October 2012–28 October 2013; second year: 29
October 2013–28 October 2014; third year: 29 October 2014–30 June 2015.
c Oldest vaccine age-eligible case was 31 months old.
d Analysis restricted to exposed uninfected comparing rotavirus enzyme immunoassay (EIA)
positive to negative. Two HIV-infected children were not included in analysis.
e Weight-for-age, length-for-age, and weight-for-length z score all >−2 and mid-upper arm
circumference > 11 cm.
f Analysis restricted to stunted (length-for-age z score ≤−2) comparing rotavirus EIA positive
to negative.
g Analysis restricted to stated Vesikari score range comparing rotavirus EIA positive to
negative.
h All specific genotypes compared with EIA negative.
Figure 5. Age at diarrheal episode by rotavirus status before (1 January 2012–28
October 2012) and after (29 October 2012–30 June 2015) monovalent rotavirus vac-
cine introduction.
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manifest as resurgence in disease in older groups, and this should
310 be detectable using consistent surveillance methods.
While RV1 is known to provide heterotypic protection [17],we
found higher point estimates of VE against the G1 genotype, and
highest of all against fully homotypic G1P[8] genotypes, and low-
est for totally heterotypic strains. We have previously reported on
315 the dominance of G2 in the season following vaccine introduc-
tion in Malawi [5]. Similar ﬁndings have been reported in Aus-
tralia, Belgium, and Brazil, although whether these changes were
caused by vaccine pressure or natural variation has been debated
[31–34].Our data suggest that the rising G2 incidence at the time
320 of vaccine introduction in Malawi was likely due to temporal os-
cillation as many of the cases occurred in children age-ineligible
for vaccination (data not shown) and subsequent G2 detection
rates decreased with increasing vaccine coverage.
Despite the apparent lower VE associated with some rotavi-
325 rus genotypes, this was not associated with an increase of any
particular genotypes. Detailed characterization of the outer
capsid antigenic regions among G1P[8] strains circulating be-
fore and after vaccine introduction will be useful to evaluate
any potential vaccine-induced selection of speciﬁc antigenic
330 proﬁles. In addition, in light of the recent emergence of dou-
ble-reassortant G1P[8] on a DS-1–like genetic backbone [35],
whole-genome characterization will be important to assess
fully the role of reassortment on vaccine performance against
a variety of homotypic and heterotypic strains.
335 Our ﬁnding of VE in HIV-exposed children and in stunted
children is important for regions with high prevalence of these
conditions, and conﬁrms the immunogenicity ﬁndings of recent
studies [4, 13]. Lower VE among stunted children may be bio-
logically plausible [10, 36] but despite the differing point esti-
340 mates, the distinction was not statistically signiﬁcant [37]. We
were unable to estimate the impact of severe acute malnutrition
on vaccine effectiveness because of absence of premorbid weight
in our children. We did not collect discharge weights as surro-
gate of premorbid weight because children were often dis-
345 charged once tolerating oral intake with lessening diarrhea
even if not fully rehydrated.
Interestingly, we did not ﬁnd an association between VE and
disease severity. This may reﬂect a referral bias, in that children
observed at our hospital were either inpatients, or children un-
350 dergoing a period of observation prior to discharge. Children
with milder disease who were rapidly dismissed were more like-
ly to have been missed by study staff and less likely to produce a
fecal sample.
There were some limitations to our study. Maintaining con-
355 sistent ascertainment efforts over a period approaching 2 de-
cades is challenging. As a result, we were unable to report
population-based incidence rates, but have been able to report
on rotavirus positivity in stool. Despite 3 years of postvaccine
surveillance, analysis of speciﬁc strata still suffers from low
360 numbers and wide conﬁdence bounds, precluding adequate
power to detect speciﬁc vaccine effectiveness in risk groups.
As vaccine coverage approaches a high baseline, unvaccinated
children may no longer be representative of the general child
population [38–40]. Residual unvaccinated children may differ
365in other important ways that increase their risk of disease inde-
pendent of their lack of vaccine.
CONCLUSIONS
The rotavirus vaccination program in Malawi has led to persis-
tent reductions in the burden of disease in infants, but has not
370had apparent impact in older children in whom VE is lower.
The increasing age of rotavirus cases behoves ongoing assess-
ment in case waning immunity leads to rebound of disease. De-
spite differences in VE by genotype, no speciﬁc genotypes
persistently dominate to suggest vaccine escape. VE is unaffect-
375ed by HIV exposure and we found no signiﬁcant difference by
stunting. Our ﬁndings that rotavirus vaccination provides reli-
able reductions in disease burden in Malawi are encouraging for
other high-burden settings with ubiquitous comorbidity.
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Online Summary text
530 Rotavirus disease incidence in Malawi has progressively
declined since vaccine introduction in 2012. Effectiveness is
maintained in high-risk groups, such as HIV-exposed and mal-
nourished children, but is lower in the second year of life and
varies by rotavirus genotype.
